Overview

Opioids Drugs Market is forecasted to value over USD 31 billion by 2027 end and register a CAGR of 2.5% from the forecast period 2020-2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Opioids Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market.
According to the research study conducted by FutureWise research analysts, the Opioids Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Opioids Drugs Market are:    

• PURDUE PHARMA    
• TEVA    
• MYLAN    
• J&J  
• DEPOMED  
• INSYS
• Acura Pharmaceuticals Inc
• Allergan Plc
• Biodelivery Sciences International Inc
• Cipher Pharmaceuticals Inc
• Collegium Pharmaceutical Inc
• Daiichi Sankyo Inc
• Egalet Corp
• Hikma Pharmaceuticals Plc
• Indivior Inc
• Janssen Pharmaceuticals Inc
• Lannett Co. Inc
• Lupin Ltd
• Mylan Nv
• Pfizer Inc
• Sanofi-aventis S.A
• Sun Pharmaceutical Industries Limited (Sun Pharma)
  (Note: The list of the major players will be updated with the latest market scenario and trends)

Opioids Drugs Market Segmentation:

By Type
• Buprenorphine
• Fentanyl
• Hydrocodone
• Morphine
• Oxycodone
• Tramadol
• Others

By Application
• Pain Relief
   o Cancer Pain
   o Postoperative Pain Management
   o Low Back Pain
   o Orthopedic
   o Fibromyalgia
   o Neuropathic
• Anesthesia
• Cough Suppression
• Diarrhea Suppression
• Deaddiction

By Region
• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the Opioids Drugs Market by type, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction

         1.1 Objectives of the Study 

         1.2 Market Definition 

         1.3 Market Scope 

                1.3.1 Years Considered for the Study

                1.3.2 Market Covered                  

         1.4 Currency   

         1.5 Limitations 

         1.6 Stakeholders 

2.  Research Methodology 

         2.1 Research Data 

            2.1.1 Secondary Data

                 2.1.1.1 Key Data From Secondary Sources

            2.1.2 Primary Data

                 2.1.2.1 Key Data From Primary Sources

         2.2 Market Size Estimation 

         2.3 Market Breakdown and Data Triangulation 

         2.4 Assumptions for the Study  

3. Executive Summary

         3.1 Market Outlook

         3.2 Segment Outlook

         3.3 Competitive Insights

4. Global Opioids Drugs Market Variables, Trends & Scope

         4.1. Market Lineage Outlook

         4.2. Penetration and Growth Prospect Mapping

         4.3. Industry Value Chain Analysis

         4.4. Cost Analysis Breakdown

         4.5. Technology Overview

         4.6. Regulatory Framework

                 4.6.1. Reimbursement Framework

                 4.6.2. Standards And Compliances

5. Market Overview

         5.1. Market Dynamics

                  5.1.1. Market Driver Analysis

                            5.1.1.1. Increasing focus on Brand Protection

                            5.1.1.2. Untapped Opportunities in Emerging Regions

                  5.1.2. Market Restraint Analysis

                  5.1.3. Industry Challenges

                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Opioids Drugs Market Analysis Tools

         6.1. Industry Analysis - Porter’s

               6.1.1. Supplier Power

               6.1.2. Buyer Power

               6.1.3. Substitution Threat

               6.1.4. Threat from New Entrants

               6.1.5. Competitive Rivalry

         6.2. Pestel Analysis

               6.2.1. Political Landscape

               6.2.2. Environmental Landscape

               6.2.3. Social Landscape

               6.2.4. Technology Landscape

               6.2.5. Legal Landscape

         6.3. Major Deals And Strategic Alliances Analysis

                6.3.1. Joint Ventures

                6.3.2. Mergers and Acquisitions

                6.3.3. Licensing and Partnership

                6.3.4. Technology Collaborations

                6.3.5. Strategic Divestments

         6.4. Market Entry Strategies

         6.5. Case Studies

7. Global Opioids Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)

         7.1. Buprenorphine

         7.2.Fentanyl

         7.3.Hydrocodone

         7.4.Morphine

         7.5.Oxycodone

         7.6.Tramadol

         7.7.Others

8. Global Opioids Drugs Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)

         8.1.Pain Relief

                8.1.1. Cancer Pain

                8.1.2. Postoperative Pain Management

                8.1.3. Low Back Pain

                8.1.4. Orthopedic

                8.1.5. Fibromyalgia

                8.1.6. Neuropathic

         8.2.Anesthesia

         8.3.Cough Suppression

         8.4.Diarrhea Suppression

         8.5.Deaddiction

9.  North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs

         9.1. Introduction

         9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

            9.2.1. U.S.A

            9.2.2. Canada

            9.2.3. Mexico

         9.3. Market Size (USD Million) Forecast for North America 2020-2027

10. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

         10.1. Introduction

         10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

           10.2.1. Germany

           10.2.2. U.K

           10.2.3. France

           10.2.4. Italy

           10.2.5. Spain

           10.2.6. Russia

           10.2.7. Poland

           10.2.8. Switzerland

           10.2.9. Rest of Western Europe

11. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs

         11.1. Introduction

         11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 

             11.2.1. Japan

             11.2.2. China

             11.2.3. Singapore

             11.2.4. India

             11.2.5. Australia and New Zealand

             11.2.6. ASEAN

             11.2.7. South Korea

             11.2.8. Rest of Asia Pacific

         11.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

12. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

         12.1. Introduction

         12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                   12.2.1. Saudi Arabia

                   12.2.2. UAE

                   12.2.3. South Africa

                   12.2.4. Egypt

         12.3. Market Size (USD Million) Forecast for MEA 2020-2027

13. Rest of the World Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs

         13.1. Introduction

         13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

             13.2.1. Saudi Arabia

             13.2.2. UAE

             13.2.3. South Africa

             13.2.4. Egypt

         13.3. Market Size (USD Million) Forecast for MEA 2020-2027          

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

         14.1. PURDUE PHARMA    

                14.1.1. Company Overview

                14.1.2. Product Portfolio

                14.1.3. SWOT Analysis

                14.1.4. Financial Overview

                14.1.5. Strategic Overview

         14.2. TEVA    

                14.2.1. Company Overview

                14.2.2. Product Portfolio

                14.2.3. SWOT Analysis

                14.2.4. Financial Overview

                14.2.5. Strategic Overview

         14.3. MYLAN    

                14.3.1. Company Overview

                14.3.2. Product Portfolio

                14.3.3. SWOT Analysis

                14.3.4. Financial Overview

                14.3.5. Strategic Overview

         14.4. J&J

                14.4.1. Company Overview

                14.4.2. Product Portfolio

                14.4.3. SWOT Analysis

                14.4.4. Financial Overview

                14.4.5. Strategic Overview

         14.5. DEPOMED  

                14.5.1. Company Overview

                14.5.2. Product Portfolio

                14.5.3. SWOT Analysis

                14.5.4. Financial Overview

                14.5.5. Strategic Overview

         14.6. INSYS

                14.6.1. Company Overview

                14.6.2. Product Portfolio

                14.6.3.  SWOT Analysis

                14.6.4. Financial Overview

                14.6.5. Strategic Overview

         14.7. Acura Pharmaceuticals Inc  

                14.7.1. Company Overview

                14.7.2. Product Portfolio

                14.7.3. SWOT Analysis

                14.7.4. Financial Overview

                14.7.5. Strategic Overview

         14.8. Allergan Plc 

                14.8.1. Company Overview

                14.8.2. Product Portfolio

                14.8.3. SWOT Analysis

                14.8.4. Financial Overview

                14.8.5. Strategic Overview

         14.9. Biodelivery Sciences International Inc    

                14.9.1. Company Overview

                14.9.2. Product Portfolio

                14.9.3. SWOT Analysis

                14.9.4. Financial Overview

                14.9.5. Strategic Overview

         14.10. Cipher Pharmaceuticals Inc

                14.10.1. Company Overview

                14.10.2. Product Portfolio

                14.10.3. SWOT Analysis

                14.10.4. Financial Overview

                14.10.5. Strategic Overview

         14.11. Collegium Pharmaceutical Inc

                14.11.1. Company Overview

                14.11.2. Product Portfolio

                14.11.3. SWOT Analysis

                14.11.4. Financial Overview

                14.11.5. Strategic Overview

         14.12. Daiichi Sankyo Inc

                14.12.1. Company Overview

                14.12.2. Product Portfolio

                14.12.3.  SWOT Analysis

                14.12.4. Financial Overview

                14.12.5. Strategic Overview

         14.14. Egalet Corp   

                14.13.1. Company Overview

                14.13.2. Product Portfolio

                14.13.3. SWOT Analysis

                14.13.4. Financial Overview

                14.13.5. Strategic Overview

         14.14. Hikma Pharmaceuticals Plc  

                14.14.1. Company Overview

                14.14.2. Product Portfolio

                14.14.3. SWOT Analysis

                14.14.4. Financial Overview

                14.14.5. Strategic Overview

         14.15. Indivior Inc   

                14.15.1. Company Overview

                14.15.2. Product Portfolio

                14.15.3. SWOT Analysis

                14.15.4. Financial Overview

                14.15.5. Strategic Overview

         14.16.Janssen Pharmaceuticals Inc

                14.16.1. Company Overview

                14.16.2. Product Portfolio

                14.16.3. SWOT Analysis

                14.16.4. Financial Overview

                14.16.5. Strategic Overview

         14.17. Lannett Co. Inc

                14.17.1. Company Overview

                14.17.2. Product Portfolio

                14.17.3. SWOT Analysis

                14.17.4. Financial Overview

                14.17.5. Strategic Overview

         14.18. Lupin Ltd

                14.18.1. Company Overview

                14.18.2. Product Portfolio

                14.18.3.  SWOT Analysis

                14.18.4. Financial Overview

                14.18.5. Strategic Overview

         14.19. Mylan Nv 

                14.19.1. Company Overview

                14.19.2. Product Portfolio

                14.19.3. SWOT Analysis

                14.19.4. Financial Overview

                14.19.5. Strategic Overview

         14.20. Pfizer Inc

                14.20.1. Company Overview

                14.20.2. Product Portfolio

                14.20.3. SWOT Analysis

                14.20.4. Financial Overview

                14.20.5. Strategic Overview

         14.21. Sanofi-aventis S.A

                14.21.1. Company Overview

                14.21.2. Product Portfolio

                14.21.3. SWOT Analysis

                14.21.4. Financial Overview

                14.21.5. Strategic Overview

         14.22. Sun Pharmaceutical Industries Limited (Sun Pharma)

                14.22.1. Company Overview

                14.22.2. Product Portfolio

                14.22.3. SWOT Analysis

                14.22.4. Financial Overview

                14.22.5. Strategic Overview

15. FutureWise SME key takeaway points for Client

Tables

Figures